FDA Orange Book · active-ingredient family
Hydrochlorothiazide; moexipril hydrochloride
Hydrochlorothiazide; moexipril hydrochloride is approved as 1 brand and 4 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:UNIRETIC · NDA 020729
1
Brand (NDA)
4
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| UNIRETIC×3 | UCB INC | NDA 020729 | — | Jun 27, 1997 |
Generic (ANDA) products (4)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE×3 | HERITAGE | ANDA 202150 | — | Mar 07, 2014 | |
| MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE×3 | GLENMARK PHARMS | ANDA 090718 | — | Mar 17, 2010 | |
| MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE×3 | CHARTWELL RX | ANDA 090096 | — | Sep 25, 2008 | |
| MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE×3 | TEVA | ANDA 076980 | — | Mar 07, 2007 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Hydrochlorothiazide; moexipril hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
